Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (INDV)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (INDV).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron (REGN)
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Regeneron. The company’s shares closed last Thursday at $704.21, close to its 52-week low of $629.02.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $876.75 average price target, which is a 26.5% upside from current levels. In a report issued on April 22, Goldman Sachs also maintained a Buy rating on the stock with a $967.00 price target.
See today’s best-performing stocks on TipRanks >>
Bausch + Lomb Corporation (BLCO)
Bank of America Securities analyst Travis Steed maintained a Sell rating on Bausch + Lomb Corporation today. The company’s shares closed last Thursday at $15.73.
According to TipRanks.com, Steed is a 2-star analyst with an average return of
Bausch + Lomb Corporation has an analyst consensus of Hold, with a price target consensus of $18.60, implying a 21.4% upside from current levels. In a report released today, TipRanks – xAI also downgraded the stock to Sell with a $14.50 price target.
Indivior (INDV)
In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Indivior, with a price target of $48.00. The company’s shares closed last Thursday at $36.22.
According to TipRanks.com, Folkes is a 2-star analyst with an average return of
Currently, the analyst consensus on Indivior is a Strong Buy with an average price target of $50.67, which is a 40.9% upside from current levels. In a report released today, TipRanks – PerPlexity also upgraded the stock to Buy with a $38.00 price target.
Read More on REGN:
Disclaimer & DisclosureReport an Issue
- Regeneron price target lowered to $762 from $779 at RBC Capital
- Regeneron: Buy Rating Reiterated as Analyst Sees Melanoma Trial Sell-Off Overdone; $900 Price Target Unchanged
- Regeneron price target lowered to $917 from $923 at Barclays
- Regeneron Earnings Call Highlights Durable Growth Engine
- These Are the Stocks Reporting Earnings Today – April 29, 2026
